• No image available for this medication

    • BRANDYCAL-D

    • QTY 100
    • 100MG-3MCG
    • Tablet

BRANDYCAL-D Lifestyle Interactions

  • Dasatinib 20mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Dasatinib with grapefruit or grapefruit juice. Taking Dasatinib with grapefruit or grapefruit juice may increase side effects of Dasatinib. If you accidentally take Dasatinib with grapefruit or grapefruit juice, immediately tell your doctor about any unusual effects.
    • Notes for Professionals: Instruct patients to avoid grapefruit or grapefruit juice with dasatinib due to the potential for increased dasatinib exposure and subsequent toxicity. Dasatinib is sensitive CYP3A4 substrate and grapefruit is a strong CYP3A4 inhibitor. Coadministration of another strong CYP3A4 inhibitor increased the mean Cmax and AUC of dasatinib by 4-fold and 5-fold, respectively.

  • Dasatinib 20mg, Oral tablet

    • Interaction: Marijuana
    • Severity: Moderate
    • Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.
    • Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with dasatinib. Dasatinib is an inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with dasatinib, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.